We are live on ! Find out more
AXSM icon

Axsome Therapeutics
AXSM

226 hedge funds and large institutions have $2.65B invested in Axsome Therapeutics in 2023 Q3 according to their latest regulatory filings, with 26 funds opening new positions, 87 increasing their positions, 71 reducing their positions, and 28 closing their positions.

New
Increased
Maintained
Reduced
Closed

53% more call options, than puts

Call options by funds: $56.4M | Put options by funds: $36.8M

25% more funds holding in top 10

Funds holding in top 10: 8 → 10 (+2)

23% more repeat investments, than reductions

Existing positions increased: 87 | Existing positions reduced: 71

2.14% more ownership

Funds ownership: 78.14% → 80.28% (+2.1%)

1% more capital invested

Capital invested by funds: $2.61B → $2.65B (+$33.4M)

7% less first-time investments, than exits

New positions opened: 26 | Existing positions closed: 28

2% less funds holding

Funds holding: 231 → 226 (-5)

Holders
226
Holders Change
-5
Holders Change %
-2.16%
% of All Funds
3.59%
Holding in Top 10
10
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+25%
% of All Funds
0.16%
New
26
Increased
87
Reduced
71
Closed
28
Calls
$56.4M
Puts
$36.8M
Net Calls
+$19.5M
Net Calls Change
-$25.6M

Top Buyers

1
Citadel Advisors
Citadel Advisors
Florida
+$62.9M
2
DTC
Deep Track Capital
Connecticut
+$56.6M
3
JFG
Jefferies Financial Group
New York
+$41.4M
4
EAM
Eventide Asset Management
Massachusetts
+$25.9M
5
SCM
Soleus Capital Management
Connecticut
+$15.9M

Top Sellers

1
CAM
Cormorant Asset Management
Massachusetts
-$24.4M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$20.2M
3
APM
Avidity Partners Management
Texas
-$18.6M
4
Millennium Management
Millennium Management
New York
-$17.3M
5
IAM
Iridian Asset Management
Connecticut
-$12.5M
Name Holding Trade Value Shares
Change 		Change in
Stake
FGAM
226
Financial Gravity Asset Management
Texas
$48 -$5.38K -72 Closed
CAM
227
Cormorant Asset Management
Massachusetts
– -$24.4M -340,000 Closed
CS
228
Clear Street
New York
– -$9.45M -131,500 Closed
Alyeska Investment Group
229
Alyeska Investment Group
Illinois
– -$8.98M -125,000 Closed
Walleye Capital
230
Walleye Capital
New York
– -$6.45M -86,280 Closed
MIM
231
Monashee Investment Management
Massachusetts
– -$5.39M -75,000 Closed
LCG
232
Lisanti Capital Growth
New York
– -$2.39M -33,325 Closed
Tudor Investment Corp
233
Tudor Investment Corp
Connecticut
– -$2.18M -30,321 Closed
SCA
234
Sassicaia Capital Advisers
New York
– -$1.72M -24,000 Closed
BC
235
Brookfield Corp
Ontario, Canada
– -$1.4M -19,526 Closed
EI
236
EAM Investors
California
– -$1.3M -18,102 Closed
FAM
237
Fred Alger Management
New York
– -$1.25M -17,422 Closed
HIS
238
Harvest Investment Services
Illinois
– -$1.17M -16,349 Closed
QIM
239
Quantitative Investment Management
Virginia
– -$1.1M -15,300 Closed
Calamos Advisors
240
Calamos Advisors
Illinois
– -$917K -12,755 Closed
AAA
241
Affinity Asset Advisors
New York
– -$898K -12,500 Closed
AR
242
Advisory Research
Illinois
– -$623K -8,671 Closed
JF
243
Jump Financial
Illinois
– -$610K -8,488 Closed
CM
244
Capula Management
Cayman Islands
– -$555K -7,720 Closed
WG
245
Winton Group
United Kingdom
– -$372K -5,179 Closed
Walleye Trading
246
Walleye Trading
New York
– -$386K -5,168 Closed
American Century Companies
247
American Century Companies
Missouri
– -$280K -3,893 Closed
NC
248
NinePointTwo Capital
California
– -$258K -3,599 Closed
BRWA
249
B. Riley Wealth Advisors
Florida
– -$241K -3,347 Closed
SC
250
Shay Capital
New York
– -$230K -3,200 Closed
7 8 9
10
11

AXSM Hedge Fund Activity: Q3 2023 in Review

226 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Axsome Therapeutics (AXSM) for Q3 2023, worth a combined $2.65B — up 1.3% from $2.61B a quarter earlier.

Sellers outnumbered buyers: 28 funds closed out of AXSM and 26 opened new positions — a net loss of 2 holders — while 71 trimmed existing stakes and 87 added.

The largest buyer was Citadel Advisors, adding an estimated $62.9M. The largest seller was Cormorant Asset Management, exiting entirely with an estimated $24.4M sold.

  • 226 institutional investors held Axsome Therapeutics (AXSM) as of Q3 2023, down from 231 in Q2 2023.
  • Funds reported $2.65B of Axsome Therapeutics stock for Q3 2023, up 1.3% quarter-over-quarter.
  • 26 funds opened new Axsome Therapeutics positions in Q3 2023 and 28 closed out, a net change of -2 holders.
  • The largest Axsome Therapeutics buyer in Q3 2023 was Citadel Advisors, an estimated $62.9M added.
  • The largest Axsome Therapeutics seller in Q3 2023 was Cormorant Asset Management, an estimated $24.4M sold.

Based on aggregated 13F filings for Q3 2023.